Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|September 12, 2011
MedNet Solutions Launches the iMedNet CRO Partner Program
Advertisement
MedNet Solutions
announced the official launch of its
iMedNet
CRO Partner Program. Designed specifically to help Clinical Research Organizations (CROs) improve research efficiency, expand their service offerings, decrease internal costs, and win more business, the program provides CROs with marketplace advantages.
At the core of the program is
iMedNet EDC
, MedNet's recently released cloud-based, software-as-a-service (SaaS) eClinical solution that allows non-technical clinical research personnel to quickly and easily set up and maintain their own EDC studies.
iMedNet EDC's
intuitive study configuration tools and form libraries allow studies to be set up in days, not weeks or months. Even entire studies can be replicated in a matter of seconds.
Key additional program features include:
- Affordable Pricing – iMedNet's CRO Partner pricing model eliminates upfront fees and dramatically lowers overall costs making iMedNet EDC practical for all research initiatives–even pre-clinical and Phase I studies.
- Comprehensive iMedNet Designer Training – MedNet provides a complete iMedNet EDC training and certification program ensuring that all CRO personnel involved in the design and configuration of iMedNet studies are versed in the capabilities of the system.
- Full Sales and Marketing Support – MedNet directly supports the sales efforts of iMedNet CRO Partners with a complete range of services, from marketing materials and demonstration support, to prospective customer referrals and joint promotional activities.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
5